Clinical Trial Update: Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing Binimetinib 3 x 15 mg formulation with a 45 mg formulation in melanoma patients with BRAF V600 mutations; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Binimetinib (binimetinib)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Melanoma, BRAF V600 Mutation | Phase 1 | Status: COMPLETED | Results posted: 2024-09-19